Pancreatic Cancer Research

ResearcherTUM KlinikumNo recent work listed

Bruce Belanger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4782-5814; OpenAlex author ID A5029844099. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers

Papers 11

  1. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Co-author DOI 10.1016/j.ejca.2021.03.028↗
  2. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A … Co-author DOI 10.1016/j.pan.2020.10.029↗
  3. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.2217/fon-2020-0902↗
  4. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  5. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
  6. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  7. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Co-author DOI 10.1016/j.ejca.2018.12.007↗
  8. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers11081068↗
  9. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Co-author DOI 10.1200/jco.2016.70.1607↗
  10. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  11. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply. Last author DOI 10.1016/s0140-6736(16)30365-8↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li‐Tzong Chen · 8 shared papers, 2016–2021 · strength 0.78
  2. Jens Thomas Siveke · 6 shared papers, 2017–2021 · strength 0.61
  3. Teresa Mercade Macarulla · 4 shared papers, 2019–2021 · strength 0.46
  4. Andrea Wang‐Gillam · 5 shared papers, 2016–2020 · strength 0.44
  5. Jean‐Frédéric Blanc · 4 shared papers, 2019–2021 · strength 0.43
  6. Floris A. de Jong · 4 shared papers, 2019–2021 · strength 0.43
  7. Tanios Bekaii‐Saab · 3 shared papers, 2019–2021 · strength 0.36
  8. Daniel D. Von Hoff · 4 shared papers, 2016–2019 · strength 0.34
  9. Richard A Hubner · 3 shared papers, 2017–2019 · strength 0.26
  10. Andrew Peter Dean · 2 shared papers, 2020–2021 · strength 0.22
  11. Chung‐Pin Li · 2 shared papers, 2020 · strength 0.20
  12. Paul C. Cockrum · 1 shared paper, 2021 · strength 0.16
  13. George P. Kim · 1 shared paper, 2021 · strength 0.16
  14. Laith I. Abushahin · 1 shared paper, 2021 · strength 0.16
  15. Zev A. Wainberg · 1 shared paper, 2021 · strength 0.12
  16. Bin Zhang · 1 shared paper, 2021 · strength 0.12
  17. Farshid Dayyani · 1 shared paper, 2021 · strength 0.12
  18. Kabir Mody · 1 shared paper, 2021 · strength 0.12
  19. Kyung-Hun Lee · 1 shared paper, 2020 · strength 0.11
  20. Gyorgy Bodoky · 1 shared paper, 2020 · strength 0.11
  21. David Cunningham · 1 shared paper, 2020 · strength 0.11
  22. Hye Jin Choi · 1 shared paper, 2020 · strength 0.10
  23. Jen‐Shi Chen · 1 shared paper, 2020 · strength 0.10
  24. Kun‐Ming Rau · 1 shared paper, 2020 · strength 0.10
  25. Do‐Youn Oh · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.